Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Rating of “Hold” by Brokerages

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $5.50.

Several equities research analysts have weighed in on GUTS shares. Wall Street Zen downgraded Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings upgraded Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Craig Hallum assumed coverage on Fractyl Health in a research report on Wednesday, July 1st. They set a “buy” rating and a $4.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research note on Thursday, June 4th.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $0.66 on Monday. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $2.44. The company has a fifty day simple moving average of $0.75 and a two-hundred day simple moving average of $0.66. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41. The company has a market cap of $104.90 million, a price-to-earnings ratio of -0.75 and a beta of 2.32.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. As a group, equities analysts anticipate that Fractyl Health will post -0.53 earnings per share for the current fiscal year.

Insider Activity at Fractyl Health

In other news, Director Ian Sheffield purchased 35,000 shares of the stock in a transaction on Wednesday, June 10th. The stock was bought at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the acquisition, the director directly owned 35,000 shares of the company’s stock, valued at approximately $25,550. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William Bradley acquired 68,493 shares of the company’s stock in a transaction on Wednesday, June 10th. The stock was purchased at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the completion of the transaction, the director owned 84,622 shares in the company, valued at approximately $61,774.06. The trade was a 424.66% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 171,493 shares of company stock valued at $127,150 in the last quarter. 8.36% of the stock is currently owned by company insiders.

Institutional Trading of Fractyl Health

A number of hedge funds and other institutional investors have recently bought and sold shares of GUTS. Sanctuary Advisors LLC acquired a new position in shares of Fractyl Health during the 2nd quarter worth about $26,000. Jane Street Group LLC purchased a new position in shares of Fractyl Health in the 2nd quarter valued at about $31,000. Accredited Investors Inc. acquired a new stake in shares of Fractyl Health during the 1st quarter worth about $46,000. Scientech Research LLC acquired a new stake in shares of Fractyl Health during the 3rd quarter worth about $49,000. Finally, FNY Investment Advisers LLC lifted its stake in Fractyl Health by 84.3% during the second quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock worth $51,000 after purchasing an additional 29,920 shares during the last quarter.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.